information sur la mifépristone, le méthotrexate et le misoprostol


accueil questions

statut légal de l'avortement



You can read this page in English; Puede leer esta pagina in español;  
You can read this page in Arabic
You can read this website in Persian

  • American College of Obstetricians and Gynecologists. Practice bulletin no. 143: medical management of first-trimester abortion. Obstet Gynecol. 2014;123(3):676-92.
  • Alam A, Bracken H, Johnston H, Raghavan S, Islam N, Winikoff B, Reichenbach L. Acceptability and feasibility of mifepristone-misoprostol for menstrual regulation in Bangladesh. Int Perspect Sex Reprod Health. 2013;39(2):79-87.
  • American Psychological Association, Task Force on Mental Health and Abortion. Report of the Task Force on Mental Health and Abortion. Washington, DC: Author, 2008.
  • Baird D. Mode of action of medical methods of abortion. JAMWA. 2000; 35(3): S121-126.
  • Barbosa R, Arilha M. The Brazilian experience with Cytotec. Studies in Family Planning. 1993; 24(4): 236-240.
  • Bebbington M, Kent N, Lim K, Gagnon A, Delisle M, Tessier F, Wilson R. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet. Gynecol. 2002; 187(4): 853-857.
  • Benson J, Clark K, Gerhardt A, Randall L, Dudley S. Early abortion services in the United States: Ensuring service availability, remaining on the cutting edge of technology, and responding to client demand. Chapel Hill, NC: IPAS, 2001.
  • Beral V, Bull D, Doll R, et al. Breast cancer and abortion: Collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet. 2004;363(9414):1007-16.
  • Blanchard K, Winikoff B, Ellertson C. Misoprostol used alone for the termination of early pregnancy: A review of the evidence. Contraception 1999; 59: 209-217.
  • Blanchard K, Clark S, Winikoff B, Gaines G, Kabani G, Shannon C. Misoprostol for women's health: A review. Am J Obstet Gynecol. 2002; 99(2): 316-332.
  • Blum J, Shochet T, Lynd K, Lichtenberg ES, Fischer D, Arnesen M, Winikoff B, Blumenthal P. Can at-home semi-quantitative pregnancy tests serve as a replacement for clinical follow-up of medical abortion? A US study. Contraception. 2012;86(6):757-62.
  • Boonstra H. Mifepristone in the United States: Status and future. The Guttmacher Report on Public Policy. 2002: 4-7.
  • Bugalho A, Mocumbi S, Faúndes A, David E. Termination of pregnancies of <6 weeks gestation with a single dose of 800 µg of vaginal misoprostol. Contraception. 2000; 61: 47-50.
  • Bygdeman M, Gemzell K, Marions L. Medical termination of early pregnancy: The Swedish experience. JAMWA. 2000; 35(3): S195-196.
  • Carbonell J, Rodrigues J, Aragón S, Velazco A, Tanda R, Sánchez C, Barambio S, Chami S, Valero F. Vaginal misoprostol 1000 µg for early abortion. Contraception 2001; 63: 131-136.
  • Carbonell Esteve J, Varela L, Velazco L, Cabezas A, Tanda R, Sánchez C. Vaginal misoprostol for late first trimester abortion. Contraception. 1998; 57: 329-333.
  • Carbonell Esteve J, Varela L, Velazco A., Tanda R, Cabezas E, Sánchez C. Early abortion with 800 µg of misoprostol by the vaginal route. Contraception. 1999; 59; 219-225.
  • Charles V, Polis C, Sridhara S, Blum R. Abortion and long-term mental health outcomes: a systematic review of the evidence. Contraception 2008;78:436-50.
  • Clark S, Ellertson C, Winikoff B. Is medical abortion acceptable to all American women: The impact of sociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion. JAMWA. 2000; 35(3): S177-182.
  • Cheng L, Gülmezoglu A, Piaggio G, Ezcurra E, Van Look P. Interventions for emergency contraception. Cochrane Database Syst Rev. 2008, Issue 2.
  • Coeytaux F, Hessini L, Ejano N, Obbuyi A, Oguttu M, Osur J, Shuken K. Facilitating women's access to misoprostol through community-based advocacy in Kenya and Tanzania. Int J Gynaecol Obstet. 2014;125(1):53-5.
  • Costa S, Vessey M. Misoprostol and illegal abortion in Rio de Janeiro, Brazil. Lancet. 1993; 341: 1258-1261.
  • Coyaji K. Early medical abortion in India: Three studies and their implications for abortion services. JAMWA. 2000; 35(3): S191-194.
  • Creinin M, Schwartz J, Guido R, Pymar H. Early pregnancy failure-Current management concepts. Obstetrical and Gynecological Survey. 2001; 56(2): 105-113.
  • Creinin M. Medical abortion regimens: historical context and overview. Am J Obstet Gynecol. 2000; 183: S3-S9.
  • Creinin M, Pymar H. Medical abortion alternatives to mifepristone. JAMWA. 2000; 35(3): S127-132.
  • Creinin M, Carbonell J, Schwartz J, Varela L, Tanda R. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception. 1999; 59(1): 217-221.
  • Ellertson C, Elul B, Winikoff B. Can women use medical abortion without medical supervision? Reproductive Health Matters. 1997; 9: 149-161.
  • Ellertson C, Waldman S. The mifepristone-misoprostol regimen for early medical abortion. Current Women's Health Reports 2001; 1: 184-190.
  • Elul B, Pearlman E, Sorhaindo A, Simonds W, Westhoff C. In-depth interviews with medical abortion clients: Thoughts on the method and home administration of misoprostol. JAMWA. 2000; 35(3): S169-172.
  • Erdman JN. Harm reduction, human rights, and access to information on safer abortion. Int J Gynaecol Obstet. 2012;118(1):83-6.
  • Ewart W, Winikoff B. Toward safe and effective medical abortion. Science. 1998; 281: 520-521.
  • FIGO Working Group on Prevention of Unsafe Abortion and its Consequences; International Federation of Gynecology and Obstetrics. The combination of mifepristone and misoprostol for the termination of pregnancy. Int J Gynaecol Obstet. 2011;115(1):1-4
  • Finer L, Henshaw S. Abortion incidence and services in the United States in 2000. Perspectives on Sexual and Reproductive Health. 2003; 35(1): 6-15.
  • Foster A, Wynn L, Trussell J. Evidence of global demand for medication abortion information: An analysis of www.medicationabortion.com. Contraception. 2014; 89:174-180.
  • Foster A, Wynn L, Rouhana A, Diaz Olavarrieta C, Schaffer K, Trussell J. Providing medication abortion information to diverse communities: Use patterns of a multi-lingual website. Contraception. 2006;73:264-271.
  • Glick E. Surgical Abortion. Reno, NV: West End Women's Medical Group, 1998.
  • Gomperts R, van der Vleuten K, Jelinska K, da Costa CV, Gemzell-Danielsson K, Kleiverda G. Provision of medical abortion using telemedicine in Brazil. Contraception. 2014;89(2):129-33.
  • Gomperts RJ, Jelinska K, Davies S, Gemzell-Danielsson K, Kleiverda G. Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services. BJOG. 2008;115(9):1171-5; discussion 1175-8
  • Grossman D, Grindlay K, Buchacker T, Lane K, Blanchard K. Effectiveness and acceptability of medical abortion provided through telemedicine. Obstet Gynecol. 2011;118(2 Pt 1):296-303
  • Grossman D, Holt K, Peña M, Lara D, Veatch M, Córdova D, Gold M, Winikoff B, Blanchard K. Self-induction of abortion among women in the United States. Reprod Health Matters. 2010;18(36):136-46.
  • Hamoda H, Ashok P, Stalder C, Flett G, Kennedy E, Templeton A. A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception. Obstet Gynecol. 2004;104:1307-13.
  • Harper C, Ellertson C, Winikoff B. Could American women use mifepristone-misoprostol pills safely with less medical supervision? Contraception 2002; 65(2): 133-142.
  • Harvey S, Sherman C, Bird S, Warren J. Understanding medical abortion: Policy, politics, and women's health. Eugene, OR: Center for the Study of Women in Society, 2002.
  • Henshaw S, Finer L. The accessibility of abortion services in the United States, 2001. Perspectives on Sexual and Reproductive Health. 2003; 35(1): 16-24.
  • Jain J, Dutton C, Harwood B, Meckstroth K, Mishell D. A prospective randomize, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Human Reproduction 2002; 17(6): 1477-1482.
  • Jain J, Kuo J, Mishell D. A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Am J Obstet. Gynecol. 1999; 93(4): 571-575.
  • Jones R, Darroch J, Henshaw S. Patterns in the socioeconomic characteristics of women obtaining abortion in 2000-2001. Perspectives on Sexual and Reproductive Health. 2002; 34(5): 226-235.
  • Jones R, Henshaw S. Mifepristone for early medical abortion: Experiences in France, Great Britain and Sweden. Perspectives on Sexual and Reproductive Health. 2002; 34(3): 154-161.
  • Kapp N, Whyte P, Tang J, Jackson E, Brahmi D. A review of evidence for safe abortion care. Contraception. 2013;88(3):350-63.
  • Kahn J, Becker B, MacIsaac L, et al. The efficacy of medical abortion: a meta-analysis. Contraception. 2000; 61:29-40.
  • Kruse B. Advanced practice clinicians and medical abortion: Increasing access to care. JAMWA. 2000; 35(3): S167-168.
  • Lara D, García SG, Wilson KS, Paz F. How often and under which circumstances do Mexican pharmacy vendors recommend misoprostol to induce an abortion? Int Perspect Sex Reprod Health. 2011; 37(2):75-83.
  • Lohr PA, Wade J, Riley L, Fitzgibbon A, Furedi A. Women's opinions on the home management of early medical abortion in the UK. J Fam Plann Reprod Health Care. 2010;36(1):21-5
  • Melbye M, Wohlfahrt J, Olsen J, et al. Induced abortion and the risk of breast cancer. N Engl J Med. 1997; 336(2): 81-85.
  • National Abortion Federation. Early medical abortion with mifepristone and other agents: Overview and protocol recommendations. Washington, DC: NAF, 2002.
  • Newhall E, Winikoff B. Abortion with mifepristone and misoprostol: Regimens, efficacy, acceptability and future directions. Am J Obstet Gyncol. 2000; 183(2): S44-53.
  • Ngai S, Tang O, Chan Y, Ho P. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: Efficacy and acceptability. Human Reproduction. 2000; 15(5): 1159-1162.
  • Ngoc N, Blum J, Raghavan S, Nga N, Dabash R, Diop A, Winikoff B. Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception. 2011;83(5):410-7.
  • Peña M, Dzuba I, Smith PS, Mendoza LJ, Bousiéguez M, Martínez M, Polanco R, Villalón A, Winikoff B. Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion among women in Mexico City. Int J Gynaecol Obstet. 2014;127(1):82-5
  • Perriera L, Reeves M, Chen B, Hohmann H, Hayes J, Creinin M. Feasibility of telephone follow-up after medical abortion. Contraception. 2010;81(2):143-9.
  • Philip N, Shannon C, and Winikoff B. Misoprostol and teratogenicity: Reviewing the evidence–Report of a meeting. Robert H. Ebert Program on Critical Issues in Reproductive Health Publication Series. New York: Population Council, 2003.
  • Pymar H, Creinin M. Alternatives to mifepristone regimens for medical abortion. Am J Obstet Gyncol. 2000; 183(2). S54-64.
  • Raymond E, Shannon C, Weaver M, Winikoff B. First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review. Contraception. 2013;87(1):26-37.
  • Rodger M, Baird D. Blood loss following induction of early abortion using mifepristone (RU 486) and a prostaglandin analog (gemeprost). Contraception. 1997; 56(3): 165-168.
  • Rodriguez M, Seuc A, Kapp N, von Hertzen H, Huong N, Wojdyla D, Mittal S, Arustamyan K, Shah R; World Health Organization Research Group on Post-Ovulatory Methods of Fertility Regulation. Acceptability of misoprostol-only medical termination of pregnancy compared with vacuum aspiration: an international, multicentre trial. BJOG. 2012;119(7):817-23.
  • Rosing M, Archbald C. The knowledge, acceptability, and use of misoprostol for self-induced medical abortion in an urban US population. JAMWA. 2000; 35(3): S183-185.
  • Schaff E, Fielding S. A comparison of the abortion rights mobilization and Population Council trials. JAMWA. 2000; 35(3): S137-140.
  • Schaff E, Fielding S, Westhoff C, Ellertson C, Eisinger Stadalius L, Fuller L. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. JAMWA. 2000; 284(15): 1948-1953
  • Schonberg D, Wang L, Bennett A, Gold M, Jackson E. The accuracy of using last menstrual period to determine gestational age for first trimester medication abortion: a systematic review. Contraception. 2014;90(5):480-7.
  • Shangchun, W. Medical abortion in China. JAMWA. 2000; 35(3): S197-199.
  • Spitz I, Bardin C, Benton L, and Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Eng J Med. 1998; 338: 1241-1247.
  • Stewart F, Wells E, Flinn S, Weitz T. Early medical abortion: Issues for practice. San Francisco, CA: UCSF, Center for Reproductive Health Research and Policy, 2000.
  • Steinberg J, Russo N. Abortion and anxiety: what's the relationship? Soc Sci Med 2008;67:238–52.
  • Tang O, Miao B, Lee S, Ho P. Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: Efficacy and acceptability.Human Reproduction 2002; 17(3): 654-658.
  • Tang O, Ho P. Pilot study on the use of sublingual misoprostol for medical abortion. Contraception 2001; 64: 315-317.
  • Teal S, Harken T, Sheeder J, Westhoff C. Efficacy, acceptability and safety of medication abortion in low-income, urban Latina women. Contraception. 2009;80(5):479-83
  • Tran N, Jang M, Choe Y, Ko W, Pyo H, Kim O. Feasibility, efficacy, safety, and acceptability of mifepristone-misoprostol for medical abortion in the Democratic People's Republic of Korea. Int J Gynaecol Obstet. 2010;109(3):209-12
  • Ulmann A. The development of mifepristone: A pharmaceutical drama in three acts. JAMWA. 2000; 35(3): S117-120.
  • von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bártfai G, Ng E, Gemzell-Danielsson K, Oyunbileg A, Wu S, Cheng W, Lüdicke F, Pretnar-Darovec A, Kirkman R, Mittal S, Khomassuridze A, Apter D, Peregoudov A. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002;360:1803-10.
  • von Hertzen H. Research on regimens for early medical abortion. JAMWA. 2000; 35(3): S133-136.
  • Weitz T, Foster A, Ellertson C, Grossman D, Stewart F. “Medical” and “surgical” abortion: Rethinking the modifiers. Contraception 2004:69;77-78.
  • Wiebe E. Use of telemedicine for providing medical abortion. Int J Gynaecol Obstet. 2014;124(2):177-8.
  • Winikoff B, Dzuba I, Chong E, Goldberg A, Lichtenberg E, Ball C, Dean G, Sacks D, Crowden W, Swica Y. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol. 2012;120(5):1070-6.
  • World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ. 1993; 307 (6903): 532-537.


Si vous avez des questions sur l'interruption volontaire de grossesse par médicaments, vous pouvez visiter notre page internet sur les questions fréquemment posées.
Votre accès et l’utilisation de ce site internet sont soumis à certaines conditions d’utilisation. En consultant ce site, vous acceptez, sans limitation ou qualification, ces termes. Lire notre déclaration de confidentialité
La dernière mise à jour du site a été en janvier 2015.